Skip to main content

Vertex Pharmaceuticals ownership: holders and insider trading

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

As filed, its directors and officers own 0.2% of the shares (proxy statement, 16 Mar 2026); 1,741 institutional managers reported holding 95.5% at 30 Jun 2026. Over the last twelve months, insiders sold $132.1M of shares on the open market, $132.1M of it under 10b5-1 plans set in advance, and bought none.

From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.

Largest holders

HolderTypeSharesOf the companySourceAs of
Capital World InvestorsHolder50.3M19.86%*Form 13F30 Jun 2026
BlackRock, Inc.Holder24.1M9.51%*Form 13F30 Jun 2026
The Vanguard GroupHolder24.1M9.51%*Form 13F30 Jun 2026
Vanguard Capital ManagementHolder19.0M7.49%Schedule 13G31 Mar 2026
Capital Research Global InvestorsHolder17.8M7%Schedule 13G30 Sep 2026
State StreetInstitution11.9M4.68%*Form 13F30 Jun 2026
InvescoInstitution8.0M3.17%*Form 13F30 Jun 2026
JPMorgan ChaseInstitution6.5M2.57%*Form 13F30 Jun 2026
Geode Capital ManagementInstitution6.0M2.37%*Form 13F30 Jun 2026
Loomis Sayles & Co L PInstitution3.9M1.55%*Form 13F30 Jun 2026
UBSInstitution3.8M1.50%*Form 13F30 Jun 2026
Franklin TempletonInstitution3.3M1.32%*Form 13F30 Jun 2026
Wellington ManagementInstitution3.2M1.28%*Form 13F30 Jun 2026
Morgan StanleyInstitution3.2M1.28%*Form 13F30 Jun 2026
Bank of AmericaInstitution3.0M1.20%*Form 13F30 Jun 2026
Alliancebernstein L.p.Institution3.0M1.19%*Form 13F30 Jun 2026
Jennison Associates LLCInstitution3.0M1.18%*Form 13F30 Jun 2026
Norges BankInstitution3.0M1.17%*Form 13F30 Jun 2026
AmeripriseInstitution2.6M1.03%*Form 13F30 Jun 2026
Northern TrustInstitution2.5M0.98%*Form 13F30 Jun 2026

Insider transactions latest 25

InsiderDateTransactionSharesPriceValue
Kewalramani Reshma · CEO & President · Director6 Nov 2026Open-market sale (10b5-1 plan)−11.9K$531.53$6.31M
Brennan Daniel J. · Director20 Oct 2026Grant or award+795$503.47$400.3K
van Grunsven Jasper · EVP, CP and NPPO8 Sep 2026Grant or award+8.7K——
Ambrose Kristen · SVP & Chief Accounting Officer28 Aug 2026Grant or award+5.0K——
Tatsis Ourania · EVP, Chief Reg. & Quality Off.21 Jul 2026Grant or award+8.3K——
Sachdev Amit · EVP Chief Patient & Ext Af Off21 Jul 2026Grant or award+8.3K——
Tatsis Ourania · EVP, Chief Reg. & Quality Off.2 Jul 2026Open-market sale (10b5-1 plan)−1.5K$524.99$787.5K
McKechnie Duncan · EVP, Chief Commercial Officer2 Jul 2026Open-market sale (10b5-1 plan)−1.5K$519.00$799.8K
Liu Joy · EVP and Chief Legal Officer1 Jul 2026Open-market sale (10b5-1 plan)−828$502.71$416.2K
Bozic Carmen · EVP and CMO26 Jun 2026Open-market sale (10b5-1 plan)−596$482.50$287.6K
Bozic Carmen · EVP and CMO18 Jun 2026Open-market sale (10b5-1 plan)−1.0K$462.17$471.4K
Bozic Carmen · EVP and CMO15 Jun 2026Open-market sale (10b5-1 plan)−4.1K$450.00$1.83M
Bozic Carmen · EVP and CMO5 Jun 2026Open-market sale (10b5-1 plan)−1.7K$450.00$785.3K
Liu Joy · EVP and Chief Legal Officer1 Jun 2026Open-market sale (10b5-1 plan)−828$439.91$364.2K
Bozic Carmen · EVP and CMO29 May 2026Open-market sale (10b5-1 plan)−2.0K$450.00$888.3K
Bunnage Mark E. · EVP, Chief Scientific Officer15 May 2026Open-market sale (10b5-1 plan)−33$453.45$14.96K
Bozic Carmen · EVP and CMO15 May 2026Open-market sale (10b5-1 plan)−1.4K$453.45$614.0K
Bozic Carmen · EVP and CMO12 May 2026Open-market sale (10b5-1 plan)−7.0K$450.00$3.14M
Bhatia Sangeeta N. · Director4 May 2026Open-market sale (10b5-1 plan)−318$423.73$134.7K
Thornberry Nancy · Director1 May 2026Grant or award+472——
Schneider Jennifer · Director1 May 2026Grant or award+472——
MCKENZIE DIANA · Director1 May 2026Grant or award+943——
Liu Joy · EVP and Chief Legal Officer1 May 2026Open-market sale (10b5-1 plan)−1.1K$425.02$469.2K
Garber Alan M · Director1 May 2026Grant or award+472——
Bhatia Sangeeta N. · Director1 May 2026Grant or award+943——

Form 4 filings since 16 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.

VRTX in the terminal

Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.